NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP is notifying investors about a federal securities class action lawsuit Semler Scientific, Inc. (NASDAQ: SMLR) (“Semler” or the “Company”). PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Semler Scientific (NASDAQ: SMLR) Securities Class Action Summary Court: United States District Court for the Northern District of CaliforniaClass Period: March 10, 2021 – April 15, 2025Allegations: The filed complaint al ...

SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Semler Scientific, Inc. (NASDAQ: SMLR) securities between March 10, 2021 and April 15, 2025. Semler Scientific describes itself as a company that develops and markets technology products and services that assist its customers in evaluating and treating chronic diseases. For more information, submit a form, email attorney Aaron Dum ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Semler Scientific, Inc. due to allegations of violations of federal securities laws, particularly concerning undisclosed investigations by the DOJ [4][6]. Group 1: Legal Investigation and Claims - The firm is encouraging investors who suffered losses in Semler Scientific to contact them for discussing legal options [1][9]. - A federal securities class action has been filed against Semler Scientific, with a deadline of October 28, 2025, for investors to seek the role of lead plaintiff [4][8]. - The complaint alleges that Semler Scientific and its executives made false or misleading statements regarding a material investigation by the DOJ related to the False Claims Act [6][7]. Group 2: Company Financial Impact - Following the disclosure of the DOJ investigation and the cessation of initial settlement discussions, Semler Scientific's stock fell over 9% on the next trading day [7]. - The annual report filed with the SEC indicated that the company does not believe the amount of potential loss from the DOJ's actions can be reasonably estimated [7]. Group 3: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Semler Scientific, Inc. due to allegations of violations of federal securities laws, particularly concerning undisclosed investigations by the DOJ [2][3]. Group 1: Legal Investigation - The firm is reminding investors of the October 28, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Semler Scientific [2]. - The complaint alleges that Semler Scientific and its executives made false or misleading statements regarding a material investigation by the DOJ related to the False Claims Act [3]. Group 2: Financial Impact - Following the filing of Semler Scientific's 2024 annual report, which disclosed initial settlement discussions with the DOJ that were subsequently ceased, the company's stock fell over 9% on the next trading day [4].

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for alleged securities fraud and unlawful business practices, with a deadline for investors to join the lawsuit by October 28, 2025 [1][2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Semler and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Semler securities during the Class Period are advised to contact Pomerantz LLP to potentially become Lead Plaintiffs [2]. Group 2: Financial and Legal Context - On February 28, 2025, Semler disclosed a risk of a civil False Claims Act lawsuit from the U.S. Department of Justice regarding its QuantaFlo device, following an initial civil investigative demand received in July 2017 [4]. - Semler participated in unsuccessful settlement discussions with the DOJ in February 2025 [4]. - Following the announcement of the DOJ's involvement, Semler's stock price fell by $4.03 (9.4%) to close at $38.89 on March 3, 2025 [5]. - On April 15, 2025, Semler announced a settlement agreement with the DOJ for $29.75 million, leading to a further stock price decline of $3.40 (9.88%) to close at $31.00 on April 16, 2025 [5].

Core Viewpoint - Semler Scientific Inc. is facing a class action lawsuit due to alleged securities fraud related to undisclosed investigations by the U.S. Department of Justice regarding its QuantaFlo device and reimbursement claims [2][4]. Summary by Sections Company Background - Semler Scientific Inc. (NASDAQ: SMLR) is involved in the development of medical devices, specifically the QuantaFlo device for peripheral artery disease [2]. Legal Developments - On February 28, 2025, Semler disclosed a potential risk of a civil lawsuit from the DOJ regarding its reimbursement claims, which led to a significant drop in its stock price [2][3]. - Following unsuccessful settlement discussions with the DOJ in February 2025, Semler announced on April 15, 2025, an agreement in principle to pay $29.75 million to settle all claims, resulting in another decline in stock price [3]. Stock Performance - After the February 28 announcement, Semler's stock fell by $4.03, or 9.4%, closing at $38.89 on March 3, 2025 [3]. - Following the April 15 announcement, the stock dropped by $3.40, or 9.9%, closing at $31.00 on April 16, 2025 [3]. Allegations in the Lawsuit - The class action lawsuit alleges that Semler made materially false and misleading statements and failed to disclose a DOJ investigation into violations of the False Claims Act, which misled investors about the company's business prospects [4].

Group 1 - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Semler Scientific, Inc. securities between March 10, 2021, and April 15, 2025 [1] - Investors who purchased Semler Scientific securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A lead plaintiff must move the Court no later than October 28, 2025, to represent other class members in the litigation [3] Group 2 - The lawsuit alleges that Semler Scientific made materially false and misleading statements and failed to disclose a material investigation by the United States Department of Justice regarding violations of the False Claims Act [5] - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading public statements made by the defendants [5] Group 3 - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and recovering hundreds of millions of dollars for investors [4] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [4]

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for alleged violations of securities laws, specifically related to misleading statements about a Department of Justice investigation [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to Semler's actions between March 10, 2021, and April 15, 2025, during which investors are encouraged to contact the Schall Law Firm if they suffered losses [2]. - The complaint alleges that Semler made false and misleading statements regarding a DOJ investigation into potential violations of the False Claims Act, which were not disclosed to investors [4]. Group 2: Investor Participation - Investors who purchased Semler's securities during the class period are invited to join the lawsuit to recover their losses, with a deadline for participation set for October 29, 2025 [2]. - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [4].

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for failing to disclose an investigation by the U.S. Department of Justice regarding potential violations of the False Claims Act [1][2]. Allegations and Investigations - The lawsuit alleges that Semler Scientific did not disclose a material investigation by the DOJ into violations of the False Claims Act during the class period from March 10, 2021, to April 15, 2025 [2]. - On February 28, 2025, Semler Scientific revealed it had received an initial civil investigative demand from the DOJ in July 2017, investigating whether the company violated the False Claims Act by marketing certain tests as reimbursable by Medicare [3]. - Following unsuccessful settlement discussions with the DOJ on February 11, 2025, there was a risk of a civil lawsuit being filed, which led to a significant drop in the company's stock price [3]. Settlement and Financial Impact - On April 15, 2025, Semler Scientific announced it had reached a settlement agreement with the DOJ for $29.75 million, excluding attorney fees, but noted that further payments might be necessary and the risk of a lawsuit still exists [4]. - The announcement of the settlement led to a further decline in Semler Scientific's stock price, falling by $3.40 per share, or 9.88%, to close at $31.00 on April 16, 2025 [4]. Class Action Participation - Shareholders of Semler Scientific may be eligible to participate in the class action lawsuit, with a deadline to submit paperwork by October 28, 2025, to serve as lead plaintiff [5].

Group 1 - A class action lawsuit has been filed against Semler Scientific, Inc. for securities purchased between March 10, 2021, and April 15, 2025, inclusive [1] - Investors who purchased Semler Scientific securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - The lawsuit alleges that Semler Scientific made materially false and misleading statements and failed to disclose a material investigation by the U.S. Department of Justice regarding violations of the False Claims Act [5] Group 2 - The Rosen Law Firm, which is representing the investors, has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4] - Investors interested in joining the class action can do so by visiting the provided link or contacting the firm directly [3][6] - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7]